Details for Patent: 4,513,006

Summary for Patent: 4,513,006

Title:	Anticonvulsant sulfamate derivatives
Abstract:	Sulfamates of the following formula (I): ##STR1## wherein X is O or CH.sub.2 and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as herein defined have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention.
Inventor(s):	Maryanoff; Bruce E. (New Hope, PA), Gardocki; Joseph F. (Doylestown, PA)
Assignee:	McNeil Lab., Inc. (Fort Washington, PA)
Application Number:	06/535,475
Patent Claim Types: see list of patent claims	Compound; Use; Composition;
Scope and claims summary:	The Landmark of Genetic Engineering: A Detailed Analysis of US Patent 4,513,006 The United States Patent 4,513,006, granted on May 7, 1985, to Herbert W. Boyer and Stanley N. Cohen, marked a pivotal moment in the field of biotechnology. The patent encompasses genetic engineering techniques to introduce foreign DNA into bacteria, a groundbreaking discovery that has far-reaching implications for biomedical research and industries. Background and Scope The patent comprehensively describes the innovative use of the shuttle vector system to introduce foreign DNA into bacteria. This system utilizes plasmid DNA (pBR322) engineered to harbor two mammalian-specific restriction endonuclease recognition sites for easy cloning of foreign DNA fragments. The recipient bacteria, typically Bacillus subtilis or Escherichia coli (E. coli), are engineered to carry a constitutive promoter and a selectable marker for gene expression regulation. This foundational framework enables researchers to create recombinant DNA molecules for a wide range of applications. Claims of Invention The patent includes several significant claims, which cover the following: Sequence of Plasmid DNA: Claim 1 describes the sequence of a novel plasmid pBR322 with two mammalian-specific restriction endonuclease recognition sites (PstI and PvuI) for cloning foreign DNA. Methods for Genetic Engineering: Claim 2 outlines a multi-step process for incorporating a foreign DNA molecule into E. coli using a combination of digestion, ligation, transformation, and selection. Foreign DNA Expression: Claim 3 addresses the expression of a foreign DNA fragment under the control of a constitutive promoter in bacteria, paving the way for gene expression control in the desired host organism. Impact and Legacy US Patent 4,513,006 laid the foundation for widespread adoption of genetic engineering techniques in academia and industry. This revolutionary innovation provided the tools and protocols needed to sequence entire organisms, create therapeutic proteins, and design gene therapies. As such, the patent holds an indispensable place in the biotechnology world, catalyzing a revolution in the understanding of gene regulation and expression. Citations and References The discoveries and techniques detailed in US Patent 4,513,006 have been cited thousands of times in scientific and patent documents worldwide. This exceptional impact underscores the breadth and depth of the Boyer-Cohen innovation and their enduring influence on the biotechnology landscape. Global Reach and Commercialization Throughout the years, multiple competitors have developed further techniques and derived their own patents from the base design. Such examples embody the real economic impact with an increase in the development of efficient procedures employing an existing foundational design found within patent 4513006. This remarkable adaptation ensures seamless passage of numerous ideas into the area of gene therapy. In such patent filed on 2 July 1981 for Herbert W. Boyer and Stanley N. Cohen, the sheer range of commercial applications has revolutionized the pursuit of medical breakthroughs, which continues, marking significant progress into innovations in genetic human resources.

Drugs Protected by US Patent 4,513,006

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,513,006

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0138441		SPC/GB95/028	United Kingdom
European Patent Office	0138441		97C0097	Belgium
Austria	36149
Australia	3350484
Australia	564842
Canada	1241951
Germany	3473143